万东医疗(600055) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was approximately CNY 373.28 million, representing a 21.00% increase compared to CNY 308.50 million in the same period last year[3]. - The net profit attributable to shareholders was CNY 35.05 million, a 5.40% increase from CNY 33.26 million year-over-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 25.77% to CNY 23.27 million from CNY 31.35 million in the previous year[3]. - The company reported a net profit of CNY 1,093,370,979.96 for the period, compared to CNY 1,058,318,801.32 previously, indicating an increase of 3.31%[17]. - Total operating revenue for Q1 2025 reached ¥373,277,998.39, a 20.9% increase from ¥308,495,149.50 in Q1 2024[19]. - Net profit for Q1 2025 was ¥34,897,655.15, slightly up from ¥34,172,999.88 in Q1 2024, representing a 2.1% increase[21]. - The total comprehensive income for Q1 2025 was ¥34,897,655.15, compared to ¥34,172,999.88 in Q1 2024, indicating a 2.1% increase[21]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -208.67 million, a significant decline of 176.24% compared to CNY -75.54 million in the same period last year[3]. - Cash flow from operating activities showed a net outflow of ¥208,666,546.23 in Q1 2025, worsening from a net outflow of ¥75,537,833.74 in Q1 2024[22]. - Cash and cash equivalents at the end of Q1 2025 were ¥1,416,153,004.04, down from ¥3,015,710,522.47 at the end of Q1 2024[24]. - The company's cash and cash equivalents decreased to CNY 2,998,739,914.09 from CNY 3,586,378,532.07, representing a decline of 16.36%[15]. - The company experienced a net cash outflow from investing activities of ¥378,152,876.54 in Q1 2025, compared to a net outflow of ¥322,406,925.94 in Q1 2024[23]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5.40 billion, down 1.34% from CNY 5.47 billion at the end of the previous year[4]. - As of March 31, 2025, the total current assets of Beijing Wandong Medical Technology Co., Ltd. amounted to CNY 4,373,977,612.33, a decrease of 1.73% from CNY 4,451,370,073.15 on December 31, 2024[15]. - The total liabilities decreased to CNY 484,497,805.50 from CNY 592,503,982.96, a reduction of 18.2%[17]. - The total equity attributable to shareholders increased to CNY 4,802,598,757.68 from CNY 4,767,546,579.04, reflecting a growth of 0.73%[17]. - The company's total assets amounted to CNY 5,396,997,270.47, down from CNY 5,470,493,043.29, a decrease of 1.34%[16]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 30,385, with the largest shareholder being Midea Group Co., Ltd., holding 45.46% of the shares[12]. - The company has not reported any significant changes in shareholder relationships or actions related to financing or securities lending[14]. Expenses - Total operating costs for Q1 2025 were ¥358,486,933.72, up 29.0% from ¥277,816,152.47 in Q1 2024[19]. - Research and development expenses increased to ¥55,667,880.17 in Q1 2025, a 58.5% rise compared to ¥35,189,394.52 in Q1 2024[19]. - The company reported a significant increase in sales expenses, which rose to ¥60,600,749.81 in Q1 2025 from ¥49,631,679.54 in Q1 2024, marking a 21.5% increase[19]. Other Financial Metrics - The weighted average return on equity increased by 0.03 percentage points to 0.73% from 0.70% year-over-year[3]. - The company recognized government subsidies amounting to CNY 12.46 million, which are closely related to its normal business operations[6]. - The company experienced a 100.00% increase in trading financial assets due to the use of idle funds to purchase financial products[10]. - The company reported a significant increase of 463.02% in prepayments, primarily due to product structure adjustments and production preparations[10]. - The company's inventory decreased to CNY 197,782,413.16 from CNY 214,942,655.77, a decline of 7.99%[16]. - The non-current assets totaled CNY 1,023,019,658.14, slightly up from CNY 1,019,122,970.14[16]. - Accounts receivable increased to CNY 470,738,186.80, up 23.5% from CNY 381,205,179.51[15].